Review



kyplot data and visualization software package  (KyensLab Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    KyensLab Inc kyplot data and visualization software package
    Kyplot Data And Visualization Software Package, supplied by KyensLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/kyplot+data+and+visualization+software+package/pmc03234088-113-6-12
    Average 90 stars, based on 1 article reviews
    kyplot data and visualization software package - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Software:

    Article Title: Graded Reductions in Oxygenation Evoke Graded Reconfiguration of the Isolated Respiratory Network
    Article Snippet: .. All statistical tests were done using either KyPlot Data and Visualization software package (Kyenslab, Tokyo) or Graphpad InStat (GraphPad Software, La Jolla, CA). ..

    Article Title: Hydrogen peroxide differentially affects activity in the pre-B?tzinger complex and hippocampus
    Article Snippet: .. Statistics were calculated with either the KyPlot Data and Visualization software package (Kyenslab, Tokyo, Japan) or Graphpad InStat (Graphpad Software, La Jolla, CA). .. Statistics were calculated with either the KyPlot Data and Visualization software package (Kyenslab, Tokyo, Japan) or Graphpad InStat (Graphpad Software, La Jolla, CA).



    Similar Products

    90
    GraphPad Software Inc survival calculation tool graphpad prism
    Survival Calculation Tool Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/graphpad+prism+tool/pmc08033524__EMMM___13___e13162___s001-538-10-10
    Average 90 stars, based on 1 article reviews
    survival calculation tool graphpad prism - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc statistical calculations graphpad prism 8
    Statistical Calculations Graphpad Prism 8, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/graphpad+prism+8/pmc10962953__pnas__2318176121__sapp-139-9-9
    Average 90 stars, based on 1 article reviews
    statistical calculations graphpad prism 8 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc area under the curve (auc) calculated by graphpad prism
    Area Under The Curve (Auc) Calculated By Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/area+under+the+curve++auc++calculated+by+graphpad+prism/pm40650904-107-20-20
    Average 90 stars, based on 1 article reviews
    area under the curve (auc) calculated by graphpad prism - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc graphpad chi-square calculator
    Graphpad Chi Square Calculator, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/chi+square+calculator/pmc12264594-251-6-10
    Average 90 stars, based on 1 article reviews
    graphpad chi-square calculator - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc graphpad outlier calculator
    Graphpad Outlier Calculator, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/quickcalcs/pm40441390-177-8-11
    Average 90 stars, based on 1 article reviews
    graphpad outlier calculator - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc online t-test calculator graphpad prizm
    Online T Test Calculator Graphpad Prizm, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/online+t+test+calculator+graphpad+prizm/10__1016_slash_j__rechem__2025__102385-139-5-5
    Average 90 stars, based on 1 article reviews
    online t-test calculator graphpad prizm - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc roc curve calculated using graphpad prism software
    Roc Curve Calculated Using Graphpad Prism Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/graphpad+prism+software/pm40394099-128-20-28
    Average 90 stars, based on 1 article reviews
    roc curve calculated using graphpad prism software - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc pearson’s correlation coefficient(r) calculated in graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient(r) Calculated In Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/correlation+coefficient/pmc12064836-34-6-11
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient(r) calculated in graphpad prism - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc online calculator graphpad
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Online Calculator Graphpad, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+calculator/online+graphpad+calculator/pmc12145132-43-7-8
    Average 90 stars, based on 1 article reviews
    online calculator graphpad - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

    doi: 10.1038/s41467-025-59588-3

    Figure Lengend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Article Snippet: The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies.

    Techniques: Comparison, Clinical Proteomics, Two Tailed Test